Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ipomoea aquatica-derived exosome-like nanoparticles (IA-ELNs) are plant-derived extracellular-like nanoparticles isolated from the leaves of *Ipomoea aquatica* (water spinach). Developed by the Korea Atomic Energy Research Institute, these nanoparticles are being investigated for their potential in cancer immunotherapy. IA-ELNs function by activating dendritic cells (DCs) and promoting Th1-polarized anti-tumor immune responses. Mechanistically, they enhance DC maturation by upregulating surface markers such as CD80, CD86, MHC-I, and MHC-II, and stimulating the secretion of pro-inflammatory cytokines like IL-12p70 and TNF-α. This activation is mediated through the phosphorylation of ERK, JNK, and p38 MAPKs, as well as the activation of the NF-κB signaling pathway, ultimately leading to the proliferation of CD4+ and CD8+ T cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ipomoea aquatica-derived exosome-like nanoparticles.